Compare the Global Sales of Blockbuster Drugs Losing Patent this Year (2014)

Posted on


Compare the global sales of 2013 and 2012 of the top ten blockbuster drugs which is losing patent this year. Teva Pharmaceutical’s Copaxone is the most affected drugs in terms of sales as the sales of 2013 has increased to 4.328 billions bearing the highest loss. Least affected Drug is AbbVie’s Trilipix which has faced the decrease in sales from 1.098 billions to 303 millions.

Blockbuster Drugs Global Sales 2012-13
Blockbuster Drugs Global Sales 2012-13

 

Table: Global Sales of Blockbuster Drugs for 2012 and 2013

Brand Name Global Sales 2012 USD (b) Global Sales 2013

USD (b)

Copaxone 3.996 4.328
Nexium 3.994 3.872
Micardis/Micardis HCT 2.217 0.97
Sandostatin LAR 1.512 1.589
Exforge/Exforge HCT 1.352 1.456
Nasonex 1.268 1.335
Trilipix 1.098 0.303
Evista 1.01 1.05
Renagel/Renvela 0.861 0.75
Restasis 0.792 0.94
Advertisements

One thought on “Compare the Global Sales of Blockbuster Drugs Losing Patent this Year (2014)

    Micki said:
    May 20, 2015 at 6:03 am

    Antibiotics tend to be medicines employed in the treating bacterial infections a result of bacterias, fungi, as well as parasitic organisms.

    In the past, treating microbe infections had been quite hard.
    Actually, before the breakthrough connected with
    antibiotics, quite a few individuals getting microbial infection in no way managed to get beyond hospital bedrooms living.
    That is why the development of antibiotics ended up being probably the most essential health and fitness improvements

    Like

Comments are closed.